Literature DB >> 10356365

The SH3 and BH domains of the p85alpha adapter subunit play a critical role in regulating class Ia phosphoinositide 3-kinase function.

C A Beeton1, P Das, M D Waterfield, P R Shepherd.   

Abstract

We have investigated the role of the SH3 and BH domains in the function of the p85alpha adapter/regulatory subunit of PI 3-kinase. In these studies epitope-tagged adapter subunit constructs containing wild-type p85alpha, p85alpha lacking the SH3 domain (deltaSH3-p85alpha), or p85alpha lacking the Rac-GAP/BCR homology (BH) domain (deltaBH-p85alpha) were coexpressed with either the p110alpha or p110beta PI 3-kinase catalytic subunit in HEK293 cells. The deletion of either BH or SH3 domains had no effect on the intrinsic activity of the PI 3-kinase heterodimers. However, the ability of activated Rac to stimulate PI 3-kinase activity was only observed in heterodimers containing the p85alpha and deltaSH3-p85alpha, indicating that rac binding to the BH domain is responsible for rac-induced stimulation of class Ia PI 3-kinase. We also investigated the effect of SH3 and BH domain deletion on the ability of insulin to induce recruitment of these constructs into phosphotyrosine-containing signaling complexes. We find that p85alpha expressed alone is poorly recruited into such signaling complexes. However, when coexpressed with catalytic subunit, the p85alpha adapter subunit is recruited to an extent similar to that of endogenous p85alpha. Maximal insulin stimulation caused a similar level of recruitment of p85alpha, deltaSH3-p85alpha, and deltaBH-p85alpha to signaling complexes when these adapter subunits were coexpressed with catalytic subunit. However, there was a higher level of basal association of the deltaSH3-p85alpha and deltaBH-p85alpha with tyrosine-phosphorylated proteins, meaning that the insulin-induced fold increase in recruitment was lower for these forms of the adapter. These results indicate that the N-terminal domains of p85alpha play a critical role in the way the adapter subunit responds to growth factor stimulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10356365     DOI: 10.1006/mcbr.1999.0124

Source DB:  PubMed          Journal:  Mol Cell Biol Res Commun        ISSN: 1522-4724


  7 in total

1.  Comparison of the kinetic properties of the lipid- and protein-kinase activities of the p110alpha and p110beta catalytic subunits of class-Ia phosphoinositide 3-kinases.

Authors:  C A Beeton; E M Chance; L C Foukas; P R Shepherd
Journal:  Biochem J       Date:  2000-09-01       Impact factor: 3.857

2.  Regulation of phosphoinositide 3-kinase by its intrinsic serine kinase activity in vivo.

Authors:  Lazaros C Foukas; Caroline A Beeton; Jorgen Jensen; Wayne A Phillips; Peter R Shepherd
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

3.  Cell activation-induced phosphoinositide 3-kinase alpha/beta dimerization regulates PTEN activity.

Authors:  Vicente Pérez-García; Javier Redondo-Muñoz; Amit Kumar; Ana C Carrera
Journal:  Mol Cell Biol       Date:  2014-06-23       Impact factor: 4.272

Review 4.  The regulation of class IA PI 3-kinases by inter-subunit interactions.

Authors:  Jonathan M Backer
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

5.  Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.

Authors:  Fumihiko Furuya; John A Hanover; Sheue-yann Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-30       Impact factor: 11.205

6.  The p85alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin resistance.

Authors:  Cullen M Taniguchi; José O Aleman; Kohjiro Ueki; Ji Luo; Tomoichiro Asano; Hideaki Kaneto; Gregory Stephanopoulos; Lewis C Cantley; C Ronald Kahn
Journal:  Mol Cell Biol       Date:  2007-02-05       Impact factor: 4.272

Review 7.  Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors.

Authors:  Fumihiko Furuya; Changxue Lu; Celine J Guigon; Sheue-Yann Cheng
Journal:  Steroids       Date:  2008-10-30       Impact factor: 2.668

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.